PPD, NeoGenomics to integrate pathology testing for cancer trials

person in lab
The collaboration also hopes to offer a companion diagnostic development service, from biomarker discovery through regulatory approval and commercialization. (Michal Jarmoluk)

Pharmaceutical Product Development and NeoGenomics Laboratories plan to integrate their international pathology and molecular testing offerings, with NeoGenomics providing lab services for PPD’s contract research in cancer.

The collaboration will focus on centralized pathology review, as well as specialty lab services including flow cytometry, fluorescence in situ hybridization, immunohistochemistry, cytogenetics, molecular assays, next-generation sequencing and multi-omics multiplexing methodology.

The companies also hope to provide a companion diagnostic development service, from biomarker discovery through regulatory approval and commercialization.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

It will mainly employ NeoGenomics’ sites in the U.S. and Europe, though both companies expect to invest in PPD’s existing labs in China and Singapore. In addition, the companies will merge their IT systems, using PPD’s Preclarus management platform.

“NeoGenomics has world-class scientific talent, significant oncology trial experience, and a broad geographic presence that will allow us to further enhance our global laboratory services for oncology trials,” Christopher Fikry, M.D., executive VP of PPD Laboratories, said in a statement.

RELATED: Leading CROs, Veeva team up for open tech on trials

“Working with NeoGenomics will enable us to jointly provide a premier global oncology and specialty laboratory solution for our customers,” Fikry said.

In addition, PPD and NeoGenomics plan to assist sponsors in identifying appropriate patients for oncology clinical trials.

RELATED: PPD joins MIT think tank focused on real-world evidence

As part of a larger push to tackle the persistent obstacles in enrollment and retention, PPD teamed up with Acurian earlier this year to offer a new “patient concierge service” to guide participants through clinical trials and manage logistics for the duration of a study. The services will include appointment and medication reminders, experience feedback, device training, and transportation and reimbursement support.

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.